Experimental Pharmacology Strategies for Natural Bioactive Peptide Translation

Bioactive peptides derived from natural sources, including marine organisms, plants, microbes, and fermented foods, demonstrate significant antimicrobial, antihypertensive, antioxidant, and anticancer activities. Despite their biological potential, clinical translation remains severely hindered by poor oral bioavailability, rapid proteolytic degradation, suboptimal pharmacokinetic profiles, and inconsistencies in sourcing and standardization.

This review critically examines experimental pharmacology strategies designed to address these translational barriers. The authors evaluate approaches ranging from in vitro permeability models and in vivo pharmacokinetic profiling to chemical modifications such as cyclization, D-amino acid substitution, N-methylation, and PEGylation. Advanced delivery systems including liposomes, polymeric nanoparticles, and pH-responsive hydrogels are also assessed alongside emerging AI/ML-guided approaches.

Key findings indicate that most unmodified natural peptides display apparent permeability coefficients below 5×10−7 cm/s and plasma half-lives shorter than 15 minutes. Chemical modifications and nanocarrier systems demonstrably improve absorption and extend half-life, with reported increases in oral bioavailability of 3- to 10-fold in preclinical models. Success stories such as ziconotide and lactotripeptides IPP/VPP highlight the decisive role of integrated experimental pharmacology data compared to stalled candidates.

Critical gaps remain, including limited human pharmacokinetic evidence, scalability of nanocarriers under GMP conditions, and harmonized regulatory pathways for natural-origin peptides. The authors emphasize that rigorous experimental pharmacology, rather than bioactivity alone, is the key to bridging the bench-to-bedside gap. A standardized translational workflow from discovery to IND filing is proposed to accelerate clinical application of these promising molecules.